Amorfix Life Sciences je 56 člen EDMA

Amorfix Turns into EDMA 56th Member
EDMA, the European Diagnostic Manufacturers Association welcomes Amorfix Life Sciences as a new corporate member, bringing the Association’s overall membership up to 34 major IVD companies and 22 National Associations. The most recent EDMA Member is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases.

Amorfix develops new methods for the diagnosis and treatment of Aggregated Misfolded Protein (AMP) diseases of the brain. These include Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer, Amyotrophic Lateral Sclerosis and Parkinson.

The biotechnology company was formed in January 2004 to commercialise the advances in the epitope protection (EP) technologies discovered at the University of Toronto by Dr. Neil Cashman (currently Chief Scientific Officer and Co-founder of Amorfix) and Dr. Marty Lehto. The company uses this new knowledge to develop diagnostic kits, therapeutics and prophylactics for the AMP diseases.

EDMA looks forward to a fruitful co-operation with Amorfix in making a real difference in health and life quality.

Background:
EDMA, the European Diagnostic Manufacturers Association represents National Associations and major companies engaged in the research, development, manufacture or distribution of In Vitro Diagnostic (IVD) medical devices in Europe. Through its affiliated National Associations, EDMA represents in total more than 500 companies (or over 700 legal entities) across Europe. The mission of EDMA is to raise awareness of the importance, usefulness and added-value that diagnostic information can provide to healthcare. For this purpose, EDMA cooperates with European institutions, patients groups, trade associations, health professionals and academia to support an appropriate regulatory system, to work towards a realistic economic environment for healthcare in Europe and to be an effective voice in globalisation.
For more information, please visit EDMA website or contact:
Gloria Galán, EDMA Communications & Public Affairs Manager (Tel. +32 2 777 02 77)